Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

Ryuji Koike, Tsutomu Takeuchi, Katsumi Eguchi, Nobuyuki Miyasaka

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Application of biological agents targeting tumor necrosis factor-α (TNF-α) caused a paradigm shift in the treatment of rheumatoid arthritis (RA). The introduction of infliximab in 2003 and etanercept in 2005 in Japan had a significant impact on both Japanese rheumatologists and RA patients, although serious adverse effects such as bacterial pneumonia, tuberculosis and Pneumocystis jiroveci pneumonia are significant concerns. Based on the data from post-marketing surveillance in Japan and accumulating evidence worldwide, the Internal Medicine Rheumatology Study Group of the Ministry of Health, Labor and Welfare (MHLW), Japan, has updated the guidelines for the use of anti-TNF-α agents for RA, which were subsequently approved by the Board of Japan College of Rheumatology (JCR). In the present revised guidelines, we combined the guidelines for use of each of infliximab and etanercept together with some modifications and precautions, paying special attention to serious adverse reactions. Although it is still controversial whether the use of TNF-α blocking agents per se increases the risk of infection or not, bacterial pneumonia, regardless of the pathogens, is the most frequent complications in RA. The risk factors associated with pneumonia identified in the post-marketing surveillance of infliximab in Japan are presented in this guideline. The diagnostic algorithm is also designed for early diagnosis and treatment of pulmonary lesions seen during the treatment of biological agents. Preventive measures and precautions against tuberculosis, another frequent and significant complication in Japan, are also described. Furthermore, risk factors for developing Pneumocystis pneumonia, which uniquely occurs at 30- to 50-fold frequency under TNF-α blockade therapy in Japan, are described here and its preventive measures are discussed. It is stressed that secondary-care rheumatologists should be better familiarized with the proper use of TNF-α blocking agents and be alert to any adverse events for a better management of RA patients.

Original languageEnglish
Pages (from-to)451-458
Number of pages8
JournalModern Rheumatology
Volume17
Issue number6
DOIs
Publication statusPublished - 2007 Dec
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Japan
Guidelines
Tumor Necrosis Factor-alpha
Bacterial Pneumonia
Pneumocystis Pneumonia
Biological Factors
Rheumatology
Marketing
Tuberculosis
Pneumocystis carinii
Secondary Care
Therapeutics
Internal Medicine
Infliximab
Etanercept
Early Diagnosis
Pneumonia
Lung
Health

Keywords

  • Adverse events
  • Etanercept
  • Infliximab
  • Rheumatoid arthritis
  • Treatment guidelines
  • Tumor necrosis factor-α antagonists

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. / Koike, Ryuji; Takeuchi, Tsutomu; Eguchi, Katsumi; Miyasaka, Nobuyuki.

In: Modern Rheumatology, Vol. 17, No. 6, 12.2007, p. 451-458.

Research output: Contribution to journalArticle

Koike, Ryuji ; Takeuchi, Tsutomu ; Eguchi, Katsumi ; Miyasaka, Nobuyuki. / Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. In: Modern Rheumatology. 2007 ; Vol. 17, No. 6. pp. 451-458.
@article{246962769f844ca39bc9c13f69c20d06,
title = "Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis",
abstract = "Application of biological agents targeting tumor necrosis factor-α (TNF-α) caused a paradigm shift in the treatment of rheumatoid arthritis (RA). The introduction of infliximab in 2003 and etanercept in 2005 in Japan had a significant impact on both Japanese rheumatologists and RA patients, although serious adverse effects such as bacterial pneumonia, tuberculosis and Pneumocystis jiroveci pneumonia are significant concerns. Based on the data from post-marketing surveillance in Japan and accumulating evidence worldwide, the Internal Medicine Rheumatology Study Group of the Ministry of Health, Labor and Welfare (MHLW), Japan, has updated the guidelines for the use of anti-TNF-α agents for RA, which were subsequently approved by the Board of Japan College of Rheumatology (JCR). In the present revised guidelines, we combined the guidelines for use of each of infliximab and etanercept together with some modifications and precautions, paying special attention to serious adverse reactions. Although it is still controversial whether the use of TNF-α blocking agents per se increases the risk of infection or not, bacterial pneumonia, regardless of the pathogens, is the most frequent complications in RA. The risk factors associated with pneumonia identified in the post-marketing surveillance of infliximab in Japan are presented in this guideline. The diagnostic algorithm is also designed for early diagnosis and treatment of pulmonary lesions seen during the treatment of biological agents. Preventive measures and precautions against tuberculosis, another frequent and significant complication in Japan, are also described. Furthermore, risk factors for developing Pneumocystis pneumonia, which uniquely occurs at 30- to 50-fold frequency under TNF-α blockade therapy in Japan, are described here and its preventive measures are discussed. It is stressed that secondary-care rheumatologists should be better familiarized with the proper use of TNF-α blocking agents and be alert to any adverse events for a better management of RA patients.",
keywords = "Adverse events, Etanercept, Infliximab, Rheumatoid arthritis, Treatment guidelines, Tumor necrosis factor-α antagonists",
author = "Ryuji Koike and Tsutomu Takeuchi and Katsumi Eguchi and Nobuyuki Miyasaka",
year = "2007",
month = "12",
doi = "10.1007/s10165-007-0626-3",
language = "English",
volume = "17",
pages = "451--458",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

AU - Koike, Ryuji

AU - Takeuchi, Tsutomu

AU - Eguchi, Katsumi

AU - Miyasaka, Nobuyuki

PY - 2007/12

Y1 - 2007/12

N2 - Application of biological agents targeting tumor necrosis factor-α (TNF-α) caused a paradigm shift in the treatment of rheumatoid arthritis (RA). The introduction of infliximab in 2003 and etanercept in 2005 in Japan had a significant impact on both Japanese rheumatologists and RA patients, although serious adverse effects such as bacterial pneumonia, tuberculosis and Pneumocystis jiroveci pneumonia are significant concerns. Based on the data from post-marketing surveillance in Japan and accumulating evidence worldwide, the Internal Medicine Rheumatology Study Group of the Ministry of Health, Labor and Welfare (MHLW), Japan, has updated the guidelines for the use of anti-TNF-α agents for RA, which were subsequently approved by the Board of Japan College of Rheumatology (JCR). In the present revised guidelines, we combined the guidelines for use of each of infliximab and etanercept together with some modifications and precautions, paying special attention to serious adverse reactions. Although it is still controversial whether the use of TNF-α blocking agents per se increases the risk of infection or not, bacterial pneumonia, regardless of the pathogens, is the most frequent complications in RA. The risk factors associated with pneumonia identified in the post-marketing surveillance of infliximab in Japan are presented in this guideline. The diagnostic algorithm is also designed for early diagnosis and treatment of pulmonary lesions seen during the treatment of biological agents. Preventive measures and precautions against tuberculosis, another frequent and significant complication in Japan, are also described. Furthermore, risk factors for developing Pneumocystis pneumonia, which uniquely occurs at 30- to 50-fold frequency under TNF-α blockade therapy in Japan, are described here and its preventive measures are discussed. It is stressed that secondary-care rheumatologists should be better familiarized with the proper use of TNF-α blocking agents and be alert to any adverse events for a better management of RA patients.

AB - Application of biological agents targeting tumor necrosis factor-α (TNF-α) caused a paradigm shift in the treatment of rheumatoid arthritis (RA). The introduction of infliximab in 2003 and etanercept in 2005 in Japan had a significant impact on both Japanese rheumatologists and RA patients, although serious adverse effects such as bacterial pneumonia, tuberculosis and Pneumocystis jiroveci pneumonia are significant concerns. Based on the data from post-marketing surveillance in Japan and accumulating evidence worldwide, the Internal Medicine Rheumatology Study Group of the Ministry of Health, Labor and Welfare (MHLW), Japan, has updated the guidelines for the use of anti-TNF-α agents for RA, which were subsequently approved by the Board of Japan College of Rheumatology (JCR). In the present revised guidelines, we combined the guidelines for use of each of infliximab and etanercept together with some modifications and precautions, paying special attention to serious adverse reactions. Although it is still controversial whether the use of TNF-α blocking agents per se increases the risk of infection or not, bacterial pneumonia, regardless of the pathogens, is the most frequent complications in RA. The risk factors associated with pneumonia identified in the post-marketing surveillance of infliximab in Japan are presented in this guideline. The diagnostic algorithm is also designed for early diagnosis and treatment of pulmonary lesions seen during the treatment of biological agents. Preventive measures and precautions against tuberculosis, another frequent and significant complication in Japan, are also described. Furthermore, risk factors for developing Pneumocystis pneumonia, which uniquely occurs at 30- to 50-fold frequency under TNF-α blockade therapy in Japan, are described here and its preventive measures are discussed. It is stressed that secondary-care rheumatologists should be better familiarized with the proper use of TNF-α blocking agents and be alert to any adverse events for a better management of RA patients.

KW - Adverse events

KW - Etanercept

KW - Infliximab

KW - Rheumatoid arthritis

KW - Treatment guidelines

KW - Tumor necrosis factor-α antagonists

UR - http://www.scopus.com/inward/record.url?scp=37449017748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37449017748&partnerID=8YFLogxK

U2 - 10.1007/s10165-007-0626-3

DO - 10.1007/s10165-007-0626-3

M3 - Article

C2 - 18084695

AN - SCOPUS:37449017748

VL - 17

SP - 451

EP - 458

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 6

ER -